FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060781103> ?p ?o ?g. }

• W2060781103 endingPage "30" @default.
• W2060781103 startingPage "22" @default.
• W2060781103 abstract "Study Objective To evaluate the relationship between voriconazole dose and corresponding serum concentrations in obese and overweight immunocompromised patients. Design Retrospective medical record review. Setting National Cancer Institute–designated comprehensive cancer center. Patients A total of 92 patients with hematologic malignancies and/or hematopoietic stem cell transplants who received voriconazole and had reported steady-state serum concentrations (peak, random, or trough) during 2005–2010; 124 serum concentrations were available for analysis. Measurements and Main Results Data on patient demographics, voriconazole concentrations, and other clinical and safety data were collected. Patients were stratified based on body mass index (BMI). Patients with higher BMIs tended to have significantly higher median random voriconazole concentrations with intravenous administration (6.4 mg/L for BMI ≥ 25 kg/m2 vs 2.8 mg/L for BMI < 25 kg/m2, p=0.04). This trend was more notable with the intravenous than the oral formulations. With the oral formulation, patients with a BMI of 25 kg/m2 or greater had a median random concentration of 2.8 mg/L compared with 2.0 mg/L in patients with a BMI less than 25 kg/m2 (p=0.18). Patients with a BMI of 25 kg/m2 or greater also had a higher median daily voriconazole dose (640 vs 400 mg, p<0.001). No significant differences were noted in factors that would affect oral absorption of voriconazole (e.g., graft-versus-host disease) among BMI groups. When comparing all voriconazole concentrations, higher concentrations were associated with a greater percentage of patients who had alanine aminotransferase levels of more than 3 times the upper limit of normal. Patients with voriconazole random concentrations of 2 mg/L or greater had higher response rates (50%) than patients with concentrations lower than 2 mg/L (33%). Conclusion Standard voriconazole dosing using actual body weight in obese and overweight patients resulted in higher associated serum concentrations. Dosing using adjusted body weight may be necessary in this population in order to achieve optimal concentrations while preventing the potential for increased toxicity." @default.
• W2060781103 created "2016-06-24" @default.
• W2060781103 creator A5002744111 @default.
• W2060781103 creator A5014802274 @default.
• W2060781103 creator A5027896664 @default.
• W2060781103 creator A5029728911 @default.
• W2060781103 creator A5039725610 @default.
• W2060781103 date "2013-01-01" @default.
• W2060781103 modified "2023-09-27" @default.
• W2060781103 title "Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review" @default.
• W2060781103 cites W1964720826 @default.
• W2060781103 cites W1982177139 @default.
• W2060781103 cites W1987619489 @default.
• W2060781103 cites W1995236993 @default.
• W2060781103 cites W1998696106 @default.
• W2060781103 cites W2016465981 @default.
• W2060781103 cites W2035238837 @default.
• W2060781103 cites W2037993288 @default.
• W2060781103 cites W2039162997 @default.
• W2060781103 cites W2046859247 @default.
• W2060781103 cites W2047682827 @default.
• W2060781103 cites W2051816101 @default.
• W2060781103 cites W2056863521 @default.
• W2060781103 cites W2063905878 @default.
• W2060781103 cites W2075019606 @default.
• W2060781103 cites W2082695689 @default.
• W2060781103 cites W2090225402 @default.
• W2060781103 cites W2098175638 @default.
• W2060781103 cites W2099769947 @default.
• W2060781103 cites W2102934589 @default.
• W2060781103 cites W2106243271 @default.
• W2060781103 cites W2109814431 @default.
• W2060781103 cites W2137880466 @default.
• W2060781103 cites W2139043187 @default.
• W2060781103 cites W2142482664 @default.
• W2060781103 cites W2146052740 @default.
• W2060781103 cites W2146558016 @default.
• W2060781103 cites W2162857158 @default.
• W2060781103 cites W2166734004 @default.
• W2060781103 cites W2171105924 @default.
• W2060781103 cites W2618073389 @default.
• W2060781103 cites W4237615604 @default.
• W2060781103 doi "https://doi.org/10.1002/phar.1156" @default.
• W2060781103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23307541" @default.
• W2060781103 hasPublicationYear "2013" @default.
• W2060781103 type Work @default.
• W2060781103 sameAs 2060781103 @default.
• W2060781103 citedByCount "29" @default.
• W2060781103 countsByYear W20607811032014 @default.
• W2060781103 countsByYear W20607811032015 @default.
• W2060781103 countsByYear W20607811032016 @default.
• W2060781103 countsByYear W20607811032017 @default.
• W2060781103 countsByYear W20607811032018 @default.
• W2060781103 countsByYear W20607811032019 @default.
• W2060781103 countsByYear W20607811032020 @default.
• W2060781103 countsByYear W20607811032021 @default.
• W2060781103 countsByYear W20607811032022 @default.
• W2060781103 countsByYear W20607811032023 @default.
• W2060781103 crossrefType "journal-article" @default.
• W2060781103 hasAuthorship W2060781103A5002744111 @default.
• W2060781103 hasAuthorship W2060781103A5014802274 @default.
• W2060781103 hasAuthorship W2060781103A5027896664 @default.
• W2060781103 hasAuthorship W2060781103A5029728911 @default.
• W2060781103 hasAuthorship W2060781103A5039725610 @default.
• W2060781103 hasConcept C126322002 @default.
• W2060781103 hasConcept C141071460 @default.
• W2060781103 hasConcept C16005928 @default.
• W2060781103 hasConcept C167135981 @default.
• W2060781103 hasConcept C2779548794 @default.
• W2060781103 hasConcept C2780221984 @default.
• W2060781103 hasConcept C2780586474 @default.
• W2060781103 hasConcept C2780690907 @default.
• W2060781103 hasConcept C71924100 @default.
• W2060781103 hasConcept C90924648 @default.
• W2060781103 hasConceptScore W2060781103C126322002 @default.
• W2060781103 hasConceptScore W2060781103C141071460 @default.
• W2060781103 hasConceptScore W2060781103C16005928 @default.
• W2060781103 hasConceptScore W2060781103C167135981 @default.
• W2060781103 hasConceptScore W2060781103C2779548794 @default.
• W2060781103 hasConceptScore W2060781103C2780221984 @default.
• W2060781103 hasConceptScore W2060781103C2780586474 @default.
• W2060781103 hasConceptScore W2060781103C2780690907 @default.
• W2060781103 hasConceptScore W2060781103C71924100 @default.
• W2060781103 hasConceptScore W2060781103C90924648 @default.
• W2060781103 hasIssue "1" @default.
• W2060781103 hasLocation W20607811031 @default.
• W2060781103 hasLocation W20607811032 @default.
• W2060781103 hasOpenAccess W2060781103 @default.
• W2060781103 hasPrimaryLocation W20607811031 @default.
• W2060781103 hasRelatedWork W1524377315 @default.
• W2060781103 hasRelatedWork W2002120878 @default.
• W2060781103 hasRelatedWork W2003938723 @default.
• W2060781103 hasRelatedWork W2047967234 @default.
• W2060781103 hasRelatedWork W2118496982 @default.
• W2060781103 hasRelatedWork W2439875401 @default.
• W2060781103 hasRelatedWork W2460841817 @default.
• W2060781103 hasRelatedWork W3116281322 @default.
• W2060781103 hasRelatedWork W4238867864 @default.

• next